Impaired driving is a major cause of preventable death worldwide. Alcohol-impaired driving accounted for a mean of 19% (range, 3%-34%) of the motor vehicle crash deaths in 20 countries in 2016 1 ; in 2018, 29% of the 36 560 crash deaths in the US were attributed to impaired driving. 2 By comparison, driving under the influence of cannabis was estimated to account for 8700 road traffic deaths worldwide in 2013. 3 Alcohol and cannabis are often consumed together, and their combined use is associated with greater crash risk than the use of either substance alone. 3 Notably, cannabinoids are the most commonly detected other drugs (besides alcohol) in fatally injured drivers (up to 15% in urban areas), and the prevalence is increasing. 4,5 Understanding and addressing cannabis-impaired driving has challenges that differ from alcohol-impaired driving. Cannabis is not limited to a single drug. Recreational cannabis generally contains both Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), among dozens of other cannabinoids. The best evidence for beneficial effects of cannabinoids are for the use of CBD to treat rare pediatric convulsive disorders. 6 A National Academy of Sciences panel cited substantial evidence for modest effects of cannabinoids for chronic pain, nausea and vomiting associated with chemotherapy, and spasticity of multiple sclerosis. 7 However, cannabinoids used for the treatment of disorders and their symptoms are largely pharmaceutical-grade products (ie, not smoked or vaped products) that contain synthetic THC or combinations of THC and CBD. The majority of cannabis products available and used are not specific pharmaceutically prepared cannabinoids in well-studied doses, and dose labels often misrepresent actual contents. Thus, assessing cannabis exposure is complex.Furthermore, unlike alcohol, cannabinoid level does not correspond to performance impairment or perceived intoxication, which may persist long after peak levels can be measured. In addition, when cannabinoids are detected in drivers involved in fatal crashes, other drugs are often also detected. Consumption of THC, which produces short-term intoxication and positive mood, 8 has been demonstrated in laboratory studies to impair motor performance and cognitive function required for safe driving. 3 The effects of CBD, of THC combined with CBD, of cannabinoids with other substances, and the effects of multiple daily doses or repeated long-term cannabinoid use on driving performance are less well-studied.In this issue of JAMA, a crossover clinical trial by Arkell and colleagues 9 tested whether consumption of specific doses of THC and CBD resulted in driving impairment, as measured by